Oct 01, 2020
Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
Aug 13, 2020
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Jun 17, 2020
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 09, 2020
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
May 18, 2020
Akcea Announces Appointment of New Chief Financial Officer
May 07, 2020
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
May 06, 2020
Ionis reports first quarter 2020 financial results and recent business achievements
May 05, 2020
Akcea Reports Financial Results and Highlights for First Quarter 2020
Apr 20, 2020
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Apr 14, 2020
n-Lorem Foundation receives $500,000 donation for providing experimental antisense medicines to treat patients with ultra-rare diseases
Apr 02, 2020
Dynacure Announces EUR50M ($55M) Series C Financing
Mar 12, 2020
n-Lorem Foundation receives additional support for providing "n of 1" experimental antisense medicines to treat patients with ultra-rare diseases
Feb 26, 2020
Ionis provides fourth quarter and full year 2019 financial results
Jan 22, 2020
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 09, 2020
Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Jan 08, 2020
n-Lorem Foundation established to charitably provide antisense medicines to treat patients with ultra-rare diseases
Jan 07, 2020
Ionis' neurological franchise marks year of achievement
Nov 21, 2019
Global spinal muscular atrophy treatment market is expected to grow with a CAGR of 12.9% over the forecast period from 2019-2025
Nov 06, 2019
Ionis provides third quarter financial results and improved 2019 guidance
Oct 28, 2019
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference